1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32278
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlexiadis M.en
dc.contributor.authorJobling T.en
dc.contributor.authorMcNeilage J.en
dc.contributor.authorFuller P.J.en
dc.date.accessioned2021-05-14T10:55:57Zen
dc.date.available2021-05-14T10:55:57Zen
dc.date.copyright2005en
dc.date.created20050812en
dc.date.issued2012-10-17en
dc.identifier.citationClinical Endocrinology. 63 (1) (pp 111-115), 2005. Date of Publication: July 2005.en
dc.identifier.issn0300-0664en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/32278en
dc.description.abstractObjective: The human DIMINUTO/DWARF1 homolog seladin-1/DHCR24 has been recently reported to be up-regulated in adrenocortical adenomas. Seladin-1 expression has been reported in the normal ovary. Granulosa cell tumours of the ovary (GCT) as with adrenocortical adenomas arise from a steroidogenic tissue, respond to pituitary hormone stimulation and synthesize steroid hormones. Design(s): To test the hypothesis that seladin-1 may also have a role in the pathogenesis of GCT, we determined the expression of seladin-1 in a cohort of GCT and in mucinous and serous cystadenocarcinomas and in normal ovary. Measurements: Expression was determined by RT-PCR using gene specific primers and probes combined with Southern blot analysis of the PCR products. Result(s): Seladin-1 expression was identified in the normal ovary, mucinous cystadenocarcinomas and serous cystadenocarcinomas of the ovary whereas no expression was observed in the GCT. Conclusion(s): Based on our results, seladin-1 is not expressed in the granulosa cells or at least not in those that give rise to GCT. © 2005 Blackwell Publishing Ltd.en
dc.languageenen
dc.languageEnglishen
dc.publisherBlackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)en
dc.titleSeladin-1/DHCR24 expression in normal ovary, ovarian epithelial and granulosa tumours.en
dc.typeArticleen
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/j.1365-2265.2005.02308.xen
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid15963070 [http://www.ncbi.nlm.nih.gov/pubmed/?term=15963070]en
dc.identifier.source40966411en
dc.identifier.institution(Fuller, Alexiadis, Jobling, McNeilage) Prince Henry's Institute of Medical Research, Department of Gynaecology Oncology, Monash Medical Centre, Clayton, Vic. 3168, Australia (Fuller) Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, Vic. 3168, Australiaen
dc.description.addressP.J. Fuller, Prince Henry's Institute of Medical Research, PO Box 5152, Clayton, Vic. 3168, Australia. E-mail: peter.fuller@phimr.monash.edu.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.identifier.authoremailFuller P.J.; peter.fuller@phimr.monash.edu.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptObstetrics and Gynaecology (Monash Women's)-
Appears in Collections:Articles
Show simple item record

Page view(s)

4
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.